A carregar...
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate canc...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2686321/ https://ncbi.nlm.nih.gov/pubmed/18225455 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|